Developer docs
API playgroundTry for free, no card

Search company profiles

Biocartis NV

Full company profile

uuid02lw8vg

Namestring
Biocartis NV
Legal namestring
Biocartis NV
Websiteurl
biocartis.com
Company typeenum
Private
Founded yearint
2007
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMechelen, Belgium
HQ citystring
Mechelen
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics systems, oncology biomarker testing, companion diagnostic assays, automated PCR instruments, sample-to-answer testing
Industry4 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Molecular Diagnostics Instruments & Assays
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Idylla Instrument Sales/Leasing
TypeHardware Sales
Description

Biocartis generates revenue through the sale or lease of the Idylla molecular diagnostics instrument platform to laboratories and hospitals.

biocartis.com
2Diagnostic Test Consumables
TypeUsage Based
Description

Recurring revenue from sale of assay cartridges and test kits (Oncology Tests and Research Assays) that run on the Idylla platform. Assays include EGFR, BRAF, KRAS, NRAS-BRAF, MSI, GeneFusion, POLE-POLD1, IDH1-2, PIK3CA-AKT1, ctEGFR, ctKRAS, ctNRAS-BRAF, ThyroidPrint, and CDx MSI Test.

biocartis.com
3Pharmaceutical Companion Diagnostics Partnerships
TypeLicensing Royalties
Description

Revenue from companion diagnostic collaborations with pharmaceutical companies for drug development and patient stratification, including the Idylla CDx MSI Test for nivolumab/ipilimumab therapy selection.

biocartis.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 11 records shown
1Idylla
Description

Revolutionary, fully automated real-time PCR based molecular testing system for oncology biomarker testing

biocartis.com
+10 more records
Core offering1 text field

Biocartis develops, manufactures, and commercializes the Idylla platform, a fully automated real-time PCR-based molecular testing system that delivers sample-to-answer molecular biomarker results in approximately 3 hours. The company sells the Idylla instrument together with a menu of IVD oncology assays (EGFR, BRAF, KRAS, NRAS-BRAF, MSI, GeneFusion) including the FDA-approved and IVDR Class C-certified Idylla CDx MSI Test, an extensive portfolio of Research Use Only assays, and APIS-branded digital PCR kits. Customers include hospital and reference laboratories, oncologists, pathologists, oncology researchers, and pharmaceutical companies for companion diagnostic collaborations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Molecular biomarker results in approximately 3 hours (vs. traditional methods taking days)
+3 more records
Product overview1 text field

Biocartis offers the Idylla platform, a fully automated, real-time PCR-based molecular diagnostics system that delivers results in approximately 3 hours. The platform supports a broad menu of oncology tests including IVDR/IVDD-certified in vitro diagnostics (Idylla EGFR Mutation Test, Idylla GeneFusion Panel, Idylla BRAF/KRAS/NRAS-BRAF Mutation Tests, Idylla CDx MSI Test, Idylla MSI Test) and an extensive portfolio of Research Use Only (RUO) assays (including MSI, POLE-POLD1, ThyroidPrint, EGFR, BRAF, KRAS, NRAS-BRAF-EGFR S492R, IDH1-2, PIK3CA-AKT1, ctEGFR, ctKRAS, ctNRAS-BRAF-EGFR S492R assays). The company also offers APIS-branded digital PCR and qPCR kits for research applications. Tests process molecular biomarkers from FFPE tissue sections and liquid biopsy samples, with the CDx MSI Test serving as a companion diagnostic for immunotherapy patient selection.

Product and service11 records
1Idylla Platform
CategoryMolecular diagnostics instrument
Description

Fully automated, real-time PCR-based molecular testing instrument that delivers sample-to-answer molecular biomarker results in approximately 3 hours. Designed for use by hospital and reference laboratories without specialized molecular biology expertise.

2Idylla CDx MSI Test
CategoryCompanion diagnostic assay
Description

Companion diagnostic test that qualitatively detects microsatellite instability (MSI) status in colorectal cancer tissue samples within three hours. Indicated to identify patients who may benefit from nivolumab/ipilimumab combination therapy. FDA-approved and IVDR Class C certified.

3Idylla EGFR Mutation Test
CategoryIVD assay
Description

In vitro diagnostic test for detecting EGFR mutations, IVDR certified (A0270/6).

4Idylla BRAF Mutation Test
CategoryIVD assay
Description

In vitro diagnostic test for BRAF mutation detection (A0010/6 | IVDD).

5Idylla KRAS Mutation Test
CategoryIVD assay
Description

In vitro diagnostic test for KRAS mutation detection (A0020/6 | IVDD).

6Idylla NRAS-BRAF Mutation Test
CategoryIVD assay
Description

Combined in vitro diagnostic test for NRAS-BRAF mutation detection (A0030/6 | IVDD).

7Idylla GeneFusion Panel
CategoryIVD assay
Description

In vitro diagnostic test for gene fusion detection (A0120/6 | IVDD).

8Idylla MSI Test
CategoryIVD assay
Description

In vitro diagnostic test for microsatellite instability detection (A0100/6 | IVDD).

9Idylla MSI Assay (RUO)
CategoryResearch assay (RUO)
Description

Research Use Only assay that performs detection of microsatellite instability directly from FFPE human cancer tissue sections utilizing PCR reaction followed by high-resolution melting curve analysis. Detects mutations in 7 novel MSI loci (ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A, SULF2) with approximately 150 minutes assay turnaround time and less than 3 minutes hands-on time (A0101/6 | RUO).

10Idylla POLE-POLD1 Mutation Assay (RUO)
CategoryResearch assay (RUO)
Description

Research Use Only assay for POLE-POLD1 mutation detection (A0281/6 | RUO).

11APIS ESR1 dPCR Kit
CategoryResearch product (RUO)
Description

Digital PCR kit for ESR1 mutation detection, Research Use Only.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1A&B d.o.o
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Croatia, handling sales and support of Biocartis products in the Croatian market.

biocartis.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Australia and New Zealand, responsible for local sales, distribution, and customer support of the Idylla platform and assays.

3Advance Test Est.
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Saudi Arabia and Bahrain, providing local sales and distribution services for Biocartis products.

biocartis.com
4Advanced Technology Company
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Kuwait, handling sales and distribution of Idylla products in the Kuwaiti market.

biocartis.com
5Al Zahrawi Medical Supplies LLC
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Oman and UAE (Dubai), providing local sales, distribution, and support for Biocartis molecular diagnostics products.

biocartis.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Chile, handling sales and distribution of Biocartis products in the Chilean market.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Egypt, Tunisia, and Libya, providing local sales and distribution services for the Idylla platform in North Africa.

8UAB Nova natura
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Estonia, Latvia, and Lithuania (Baltic states), handling sales and distribution of Biocartis products.

biocartis.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Brazil, responsible for sales, distribution, and support of Idylla products in the Brazilian market.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Ecuador, handling sales and distribution of Biocartis molecular diagnostics products.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Nepal, providing local sales and distribution services for Biocartis products.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Taiwan, handling sales and distribution of Idylla products in the Taiwanese market.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Biocartis maintains partnership programs with pharmaceutical companies for companion diagnostic development and with diagnostic or biomarker companies for menu expansion. The Idylla CDx MSI Test is indicated to identify patients who may benefit from nivolumab/ipilimumab combination therapy ( Bristol-Myers Squibb products).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Diversified in vitro diagnostics company with BIOFIRE FilmArray and molecular oncology/infection panels; competes with Biocartis for lab automated testing footprints and CDx partnerships.

TypeBroad incumbent
Description

Broad diagnostics incumbent offering cobas PCR and NGS-based oncology assays (EGFR, KRAS, BRAF, MSI) on an installed hospital-lab base; overlaps with Idylla's menu but as part of a much larger IVD portfolio.

TypeDirect peer
Description

Provides sample-to-answer PCR and NGS-based molecular diagnostics, including companion diagnostics and oncology biomarker panels, with global distribution footprint similar to Biocartis.

TypeEmerging player
Description

Provides automated PCR and NGS-based oncology companion diagnostics and infectious disease kits on the Sentosa platform; partial overlap with Idylla's automated molecular diagnostics positioning.

TypeDirect peer
Description

Now part of Roche, GenMark provides the ePlex fully-automated sample-to-answer molecular platform with syndromic and oncology test menus — a close competitive analogue to Idylla's fully automated PCR value proposition.

6Abbott Molecular
TypeBroad incumbent
Description

Offers the m2000 and Alinity m automated real-time PCR molecular diagnostics platforms with oncology and infectious disease menus, competing head-to-head with Idylla for hospital and reference-lab placements.

TypeEmerging player
Description

Smaller automated molecular diagnostics company developing sample-to-answer platforms; competes with Idylla in the niche of decentralised, easy-to-use molecular testing in hospital labs.

TypeDirect peer
Description

Direct competitor with the GeneXpert line of fully automated real-time PCR systems delivering sample-to-answer molecular diagnostics across infectious disease, oncology and hospital-acquired infection menus — closest analogue to Biocartis' Idylla in workflow and use cases.

TypeDirect peer
Description

Operates the Panther Fusion fully-automated molecular platform targeting hospital and reference labs; an established automated PCR/NAAT competitor in the same capital-equipment-plus-consumables model as Idylla.

TypeEmerging player
Description

Molecular diagnostics and immunoassay provider offering PCR-based assays for hospital and reference labs; an adjacent automated molecular competitor with overlapping customer targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biocartis NV

Molecular Diagnostics Instruments & Assaysbiocartis.com

Biocartis NV firmographics

Firmographics
Name
Biocartis NV
Legal name
Biocartis NV
Website
https://biocartis.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

Biocartis NV industry classification

Industry
Product category
Molecular Diagnostics Instruments & Assays
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Molecular diagnostics systems
  • Oncology biomarker testing
  • Companion diagnostic assays
  • Automated PCR instruments
  • Sample-to-answer testing

Where Biocartis NV is headquartered

Location

Headquarters

HQ city
Mechelen
HQ country
Belgium
HQ region
Europe

Offices3 records

Markets served

Biocartis NV business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. Idylla Instrument Sales/Leasing: Biocartis generates revenue through the sale or lease of the Idylla molecular diagnostics instrument platform to laboratories and hospitals.
  2. Diagnostic Test Consumables: Recurring revenue from sale of assay cartridges and test kits (Oncology Tests and Research Assays) that run on the Idylla platform. Assays include EGFR, BRAF, KRAS, NRAS-BRAF, MSI, GeneFusion, POLE-POLD1, IDH1-2, PIK3CA-AKT1, ctEGFR, ctKRAS, ctNRAS-BRAF, ThyroidPrint, and CDx MSI Test.
  3. Pharmaceutical Companion Diagnostics Partnerships: Revenue from companion diagnostic collaborations with pharmaceutical companies for drug development and patient stratification, including the Idylla CDx MSI Test for nivolumab/ipilimumab therapy selection.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Biocartis NV product offering

Product offering

Core offering

Biocartis develops, manufactures, and commercializes the Idylla platform, a fully automated real-time PCR-based molecular testing system that delivers sample-to-answer molecular biomarker results in approximately 3 hours. The company sells the Idylla instrument together with a menu of IVD oncology assays (EGFR, BRAF, KRAS, NRAS-BRAF, MSI, GeneFusion) including the FDA-approved and IVDR Class C-certified Idylla CDx MSI Test, an extensive portfolio of Research Use Only assays, and APIS-branded digital PCR kits. Customers include hospital and reference laboratories, oncologists, pathologists, oncology researchers, and pharmaceutical companies for companion diagnostic collaborations.

Product overview

Biocartis offers the Idylla platform, a fully automated, real-time PCR-based molecular diagnostics system that delivers results in approximately 3 hours. The platform supports a broad menu of oncology tests including IVDR/IVDD-certified in vitro diagnostics (Idylla EGFR Mutation Test, Idylla GeneFusion Panel, Idylla BRAF/KRAS/NRAS-BRAF Mutation Tests, Idylla CDx MSI Test, Idylla MSI Test) and an extensive portfolio of Research Use Only (RUO) assays (including MSI, POLE-POLD1, ThyroidPrint, EGFR, BRAF, KRAS, NRAS-BRAF-EGFR S492R, IDH1-2, PIK3CA-AKT1, ctEGFR, ctKRAS, ctNRAS-BRAF-EGFR S492R assays). The company also offers APIS-branded digital PCR and qPCR kits for research applications. Tests process molecular biomarkers from FFPE tissue sections and liquid biopsy samples, with the CDx MSI Test serving as a companion diagnostic for immunotherapy patient selection.

Differentiator

Problem solved

Functional benefit

Brands

  • Idylla: Revolutionary, fully automated real-time PCR based molecular testing system for oncology biomarker testing
  • Idylla Platform
  • Idylla CDx MSI Test
  • Idylla MSI Assay
  • Idylla EGFR Mutation Test
  • Idylla BRAF Mutation Test
  • Idylla KRAS Mutation Test
  • Idylla NRAS-BRAF Mutation Test
  • Idylla GeneFusion Panel
  • APIS ESR1 dPCR Kit
  • ThyroidPrint

Products and services

  • Idylla Platform Fully automated, real-time PCR-based molecular testing instrument that delivers sample-to-answer molecular biomarker results in approximately 3 hours. Designed for use by hospital and reference laboratories without specialized molecular biology expertise.
  • Idylla CDx MSI Test Companion diagnostic test that qualitatively detects microsatellite instability (MSI) status in colorectal cancer tissue samples within three hours. Indicated to identify patients who may benefit from nivolumab/ipilimumab combination therapy. FDA-approved and IVDR Class C certified.
  • Idylla EGFR Mutation Test In vitro diagnostic test for detecting EGFR mutations, IVDR certified (A0270/6).
  • Idylla BRAF Mutation Test In vitro diagnostic test for BRAF mutation detection (A0010/6 | IVDD).
  • Idylla KRAS Mutation Test In vitro diagnostic test for KRAS mutation detection (A0020/6 | IVDD).
  • Idylla NRAS-BRAF Mutation Test Combined in vitro diagnostic test for NRAS-BRAF mutation detection (A0030/6 | IVDD).
  • Idylla GeneFusion Panel In vitro diagnostic test for gene fusion detection (A0120/6 | IVDD).
  • Idylla MSI Test In vitro diagnostic test for microsatellite instability detection (A0100/6 | IVDD).
  • Idylla MSI Assay (RUO) Research Use Only assay that performs detection of microsatellite instability directly from FFPE human cancer tissue sections utilizing PCR reaction followed by high-resolution melting curve analysis. Detects mutations in 7 novel MSI loci (ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A, SULF2) with approximately 150 minutes assay turnaround time and less than 3 minutes hands-on time (A0101/6 | RUO).
  • Idylla POLE-POLD1 Mutation Assay (RUO) Research Use Only assay for POLE-POLD1 mutation detection (A0281/6 | RUO).
  • APIS ESR1 dPCR Kit Digital PCR kit for ESR1 mutation detection, Research Use Only.

Quantifiable outcome

  • Molecular biomarker results in approximately 3 hours (vs. traditional methods taking days)
  • +3 more outcomes

Companies that use Biocartis NV

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Biocartis NV technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Biocartis NV partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered regional and core.

  • A&B d.o.oregionalChannel Partner/ Reseller/ DistributorDistributor for Croatia, handling sales and support of Biocartis products in the Croatian market.
  • Abacus dxregionalChannel Partner/ Reseller/ DistributorDistributor for Australia and New Zealand, responsible for local sales, distribution, and customer support of the Idylla platform and assays.
  • Advance Test Est.regionalChannel Partner/ Reseller/ DistributorDistributor for Saudi Arabia and Bahrain, providing local sales and distribution services for Biocartis products.
  • Advanced Technology CompanyregionalChannel Partner/ Reseller/ DistributorDistributor for Kuwait, handling sales and distribution of Idylla products in the Kuwaiti market.
  • Al Zahrawi Medical Supplies LLCregionalChannel Partner/ Reseller/ DistributorDistributor for Oman and UAE (Dubai), providing local sales, distribution, and support for Biocartis molecular diagnostics products.
  • Alatheia Medical, S.A.regionalChannel Partner/ Reseller/ DistributorDistributor for Chile, handling sales and distribution of Biocartis products in the Chilean market.
  • Alfa HealthcareregionalChannel Partner/ Reseller/ DistributorDistributor for Egypt, Tunisia, and Libya, providing local sales and distribution services for the Idylla platform in North Africa.
  • UAB Nova naturaregionalChannel Partner/ Reseller/ DistributorDistributor for Estonia, Latvia, and Lithuania (Baltic states), handling sales and distribution of Biocartis products.
  • UniscienceregionalChannel Partner/ Reseller/ DistributorDistributor for Brazil, responsible for sales, distribution, and support of Idylla products in the Brazilian market.
  • VibagregionalChannel Partner/ Reseller/ DistributorDistributor for Ecuador, handling sales and distribution of Biocartis molecular diagnostics products.
  • Web Trading Concern Pvt. Ltd.regionalChannel Partner/ Reseller/ DistributorDistributor for Nepal, providing local sales and distribution services for Biocartis products.
  • Wonderful Life Science Co Ltd.regionalChannel Partner/ Reseller/ DistributorDistributor for Taiwan, handling sales and distribution of Idylla products in the Taiwanese market.
  • Pharmaceutical and Diagnostic/Biomarker CompaniescoreStrategic or Co-development PartnerBiocartis maintains partnership programs with pharmaceutical companies for companion diagnostic development and with diagnostic or biomarker companies for menu expansion. The Idylla CDx MSI Test is indicated to identify patients who may benefit from nivolumab/ipilimumab combination therapy ( Bristol-Myers Squibb products).

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Biocartis NV competitors and assessment

Company assessment

Broad incumbents

  • bioMérieux: Diversified in vitro diagnostics company with BIOFIRE FilmArray and molecular oncology/infection panels; competes with Biocartis for lab automated testing footprints and CDx partnerships.
  • Roche Diagnostics: Broad diagnostics incumbent offering cobas PCR and NGS-based oncology assays (EGFR, KRAS, BRAF, MSI) on an installed hospital-lab base; overlaps with Idylla's menu but as part of a much larger IVD portfolio.
  • Abbott Molecular: Offers the m2000 and Alinity m automated real-time PCR molecular diagnostics platforms with oncology and infectious disease menus, competing head-to-head with Idylla for hospital and reference-lab placements.

Direct peers

  • QIAGEN: Provides sample-to-answer PCR and NGS-based molecular diagnostics, including companion diagnostics and oncology biomarker panels, with global distribution footprint similar to Biocartis.
  • GenMark Diagnostics (Roche): Now part of Roche, GenMark provides the ePlex fully-automated sample-to-answer molecular platform with syndromic and oncology test menus — a close competitive analogue to Idylla's fully automated PCR value proposition.
  • Cepheid (Danaher): Direct competitor with the GeneXpert line of fully automated real-time PCR systems delivering sample-to-answer molecular diagnostics across infectious disease, oncology and hospital-acquired infection menus — closest analogue to Biocartis' Idylla in workflow and use cases.
  • Hologic (Panther/Granger): Operates the Panther Fusion fully-automated molecular platform targeting hospital and reference labs; an established automated PCR/NAAT competitor in the same capital-equipment-plus-consumables model as Idylla.

Emerging players

  • Vela Diagnostics: Provides automated PCR and NGS-based oncology companion diagnostics and infectious disease kits on the Sentosa platform; partial overlap with Idylla's automated molecular diagnostics positioning.
  • Accelerate Diagnostics: Smaller automated molecular diagnostics company developing sample-to-answer platforms; competes with Idylla in the niche of decentralised, easy-to-use molecular testing in hospital labs.
  • QuidelOrtho: Molecular diagnostics and immunoassay provider offering PCR-based assays for hospital and reference labs; an adjacent automated molecular competitor with overlapping customer targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Biocartis NV social profiles

Digital presence

Biocartis NV financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biocartis NV leadership team

Management profile

Number of profiles

Profiles4 records

Biocartis NV subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Biocartis NV funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biocartis NV M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocartis NV

What does Biocartis NV do?

Biocartis develops, manufactures, and commercializes the Idylla platform, a fully automated real-time PCR-based molecular testing system that delivers sample-to-answer molecular biomarker results in approximately 3 hours. The company sells the Idylla instrument together with a menu of IVD oncology assays (EGFR, BRAF, KRAS, NRAS-BRAF, MSI, GeneFusion) including the FDA-approved and IVDR Class C-certified Idylla CDx MSI Test, an extensive portfolio of Research Use Only assays, and APIS-branded digital PCR kits. Customers include hospital and reference laboratories, oncologists, pathologists, oncology researchers, and pharmaceutical companies for companion diagnostic collaborations.

Is Biocartis NV a public or private company?

Biocartis NV is a private company. It is classified as unknown and is currently operating.

When was Biocartis NV founded?

Biocartis NV was founded in 2007. It employs 251 to 500 people.

Where is Biocartis NV based?

Biocartis NV is headquartered in Mechelen, Belgium, in the Europe region.

How does Biocartis NV make money?

Three revenue lines are on record. Idylla Instrument Sales/Leasing is the primary driver. The others are diagnostic Test Consumables and pharmaceutical Companion Diagnostics Partnerships.

Who are Biocartis NV's main competitors?

Broad incumbents on record are bioMérieux, Roche Diagnostics and Abbott Molecular. Direct peers are QIAGEN, GenMark Diagnostics (Roche), Cepheid (Danaher) and Hologic (Panther/Granger). Emerging players are Vela Diagnostics, Accelerate Diagnostics and QuidelOrtho.

Does Biocartis NV have an API?

No public API is recorded for Biocartis NV.

What industry is Biocartis NV in?

Biocartis NV's product category is Molecular Diagnostics Instruments & Assays. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialPress Release Biocartis NV: Biocartis To Present Initial Development Data For Ultra-Rapid Idyllatm Breast21 Assay At SABCS 2026Biocartis announced an abstract on its Idylla Breast21 assay will be presented at SABCS 2026 in San Antonio, Texas, December 8-11. The assay is an ultra-rapid, fully automated 21-gene RT-PCR test for decentralized recurrence-risk testing in early-stage breast cancer. Initial development data show strong risk class agreement with the reference method.The future of tradingPress Release Biocartis NV: Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026Biocartis announced an abstract on its Idylla Breast21 assay will be presented at SABCS 2026 in San Antonio, Texas, December 8-11. The assay is an ultra-rapid, fully automated 21-gene RT-PCR test for decentralized recurrence risk testing in early-stage breast cancer. Initial development data show strong risk class agreement with the reference method.GlobeNewswirePress Release Biocartis NV: Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026Biocartis announced an abstract on its Idylla Breast21 assay will be presented at SABCS 2026 in San Antonio, Texas, on December 8-11. The assay is an ultra-rapid, fully automated 21-gene RT-PCR test for decentralized recurrence risk testing in early-stage breast cancer. Initial development data show strong risk class agreement with the reference method.BioSpacePress Release Biocartis NV: Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology DiagnosticsBiocartis and Discovery Life Sciences announced a strategic collaboration to deliver precision oncology diagnostics, pairing Discovery's laboratory network with Biocartis' Idylla platform. The partnership will replicate rapid KRAS testing from Germany to the US, enabling harmonized biomarker results across continents. It aims to accelerate companion diagnostic readiness for global clinical trials.BioSpacePress Release Biocartis NV: Biocartis Announces Agreement with City of Hope to Explore Development of Rapid Gene Signature Test for Early Detection of Pancreatic CancerBiocartis announced an agreement with City of Hope to explore a rapid, blood-based gene signature test for early pancreatic cancer detection. The test is investigational and not yet available for diagnostic use. The collaboration aims to develop a rapid and sensitive early detection test for patients at increased risk.GlobeNewswirePress Release Biocartis NV: Biocartis to Collaborate with Medical College of Wisconsin on Breast Cancer Gene SignaturesBiocartis announced a research collaboration with the Medical College of Wisconsin to develop a rapid breast cancer gene signature test. The partnership aims to bring testing closer to patients and reduce time to optimal treatment. The test is investigational and not yet available for diagnostic use.GlobeNewswirePress Release Biocartis NV: Biocartis Receives European IVDR Certification for the Idylla™ CDx MSI TestBiocartis announced that its Idylla CDx MSI test received Class C companion diagnostic certification under the EU IVDR for colorectal cancer. The test detects MSI-H/MSS in CRC tissue samples within a single-use cartridge, requiring less than three minutes of hands-on time. The test is available in the US and will be available soon in Europe.GlobeNewswirePress Release Biocartis NV: Biocartis Receives European IVDR Certification for the Idylla™ CDx MSI TestBiocartis NV announced that its Idylla™ CDx MSI Test received Class C companion diagnostic certification under the EU's In Vitro Diagnostic Medical Device Regulation (IVDR), making it the second fully automated CDx test approved under this framework. The test qualitatively detects microsatellite instability status in colorectal cancer tissue samples within three hours and is indicated to identify patients who may benefit from nivolumab/ipilimumab combination therapy. The IVDR-certified test will be available soon across Europe and additional regions where IVDR applies, building on its existing US FDA approval.GlobeNewswirePress Release Biocartis NV: Biocartis Showcases Growing Impact of Idylla™ Platform at AMP 2025Biocartis presented multiple abstracts and a workshop on its Idylla platform at AMP 2025 in Boston. The abstracts report high concordance and accuracy for NTRK fusion, EGFR mutation, and POLE-POLD1 assays across multiple institutions. The company highlighted the platform's role in accelerating molecular testing and treatment decisions.GlobeNewswirePress Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI TestBiocartis received FDA Premarket Approval for its Idylla CDx MSI test, a fully automated cartridge-based companion diagnostic for colorectal cancer. The test detects seven biomarkers and delivers results in under three hours, aiding identification of MSI-H patients eligible for nivolumab or nivolumab plus ipilimumab.